Business
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
JERSEY CITY, N.J., February 23, 2026--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Dr
About this update from Organon & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2100,"height":315,"url":"https://media.zenfs.com/en/business-wire.com/153ae3753e427365008c83b6a9b456e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fH1v841lY3aByFIlFGeUiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/153ae3753e427365008c83b6a9b456e0","width":960,"height":144},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/9NaGsOfNB14rxDAV.lIz.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/153ae3753e427365008c83b6a9b456e0","width":1200,"height":180}},"lazy":false},{"type":"text","content":"MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health","length":124,"tagName":"p","attribs":{}},{"type":"text","content":"JERSEY CITY, N.J., February 23, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions.","length":629,"tagName":"p"},{"type":"text","content":"MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on February 24, 2025, for the prevention of pregnancy in females of reproductive potential for up to three years and is not yet commercially available. MIUDELLA offers an additional option for women seeking long-acting, reversible, hormone-free contraception. MIUDELLA contains a unique flexible frame and a fully preloaded inserter with a small, tapered insertion tube diameter of 3.7mm.1","length":691,"tagName":"p"},{"type":"text","content":"U...